Cargando…

Lung cancer biomarker testing: perspective from Europe

A questionnaire on biomarker testing previously used in central European countries was extended and distributed in Western and Central European countries to the pathologists participating at the Pulmonary Pathology Society meeting 26–28 June 2019 in Dubrovnik, Croatia. Each country was represented b...

Descripción completa

Detalles Bibliográficos
Autores principales: Thunnissen, Erik, Weynand, Birgit, Udovicic-Gagula, Dalma, Brcic, Luka, Szolkowska, Malgorzata, Hofman, Paul, Smojver-Ježek, Silvana, Anttila, Sisko, Calabrese, Fiorella, Kern, Izidor, Skov, Birgit, Perner, Sven, Dale, Vibeke G., Eri, Zivka, Haragan, Alex, Leonte, Diana, Carvallo, Lina, Prince, Spasenja Savic, Nicholson, Siobhan, Sansano, Irene, Ryska, Ales
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7354119/
https://www.ncbi.nlm.nih.gov/pubmed/32676354
http://dx.doi.org/10.21037/tlcr.2020.04.07
_version_ 1783558017866792960
author Thunnissen, Erik
Weynand, Birgit
Udovicic-Gagula, Dalma
Brcic, Luka
Szolkowska, Malgorzata
Hofman, Paul
Smojver-Ježek, Silvana
Anttila, Sisko
Calabrese, Fiorella
Kern, Izidor
Skov, Birgit
Perner, Sven
Dale, Vibeke G.
Eri, Zivka
Haragan, Alex
Leonte, Diana
Carvallo, Lina
Prince, Spasenja Savic
Nicholson, Siobhan
Sansano, Irene
Ryska, Ales
author_facet Thunnissen, Erik
Weynand, Birgit
Udovicic-Gagula, Dalma
Brcic, Luka
Szolkowska, Malgorzata
Hofman, Paul
Smojver-Ježek, Silvana
Anttila, Sisko
Calabrese, Fiorella
Kern, Izidor
Skov, Birgit
Perner, Sven
Dale, Vibeke G.
Eri, Zivka
Haragan, Alex
Leonte, Diana
Carvallo, Lina
Prince, Spasenja Savic
Nicholson, Siobhan
Sansano, Irene
Ryska, Ales
author_sort Thunnissen, Erik
collection PubMed
description A questionnaire on biomarker testing previously used in central European countries was extended and distributed in Western and Central European countries to the pathologists participating at the Pulmonary Pathology Society meeting 26–28 June 2019 in Dubrovnik, Croatia. Each country was represented by one responder. For recent biomarkers the availability and reimbursement of diagnoses of molecular alterations in non-small cell lung carcinoma varies widely between different, also western European, countries. Reimbursement of such assessments varies widely between unavailability and payments by the health care system or even pharmaceutical companies. The support for testing from alternative sources, such as the pharmaceutical industry, is no doubt partly compensating for the lack of public health system support, but it is not a viable or long‐term solution. Ideally, a structured access to testing and reimbursement should be the aim in order to provide patients with appropriate therapeutic options. As biomarker enabled therapies deliver a 50% better probability of outcome success, improved and unbiased reimbursement remains a major challenge for the future.
format Online
Article
Text
id pubmed-7354119
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-73541192020-07-15 Lung cancer biomarker testing: perspective from Europe Thunnissen, Erik Weynand, Birgit Udovicic-Gagula, Dalma Brcic, Luka Szolkowska, Malgorzata Hofman, Paul Smojver-Ježek, Silvana Anttila, Sisko Calabrese, Fiorella Kern, Izidor Skov, Birgit Perner, Sven Dale, Vibeke G. Eri, Zivka Haragan, Alex Leonte, Diana Carvallo, Lina Prince, Spasenja Savic Nicholson, Siobhan Sansano, Irene Ryska, Ales Transl Lung Cancer Res Review Article on Selected Highlights of the 2019 Pulmonary Pathology Society Biennial Meeting A questionnaire on biomarker testing previously used in central European countries was extended and distributed in Western and Central European countries to the pathologists participating at the Pulmonary Pathology Society meeting 26–28 June 2019 in Dubrovnik, Croatia. Each country was represented by one responder. For recent biomarkers the availability and reimbursement of diagnoses of molecular alterations in non-small cell lung carcinoma varies widely between different, also western European, countries. Reimbursement of such assessments varies widely between unavailability and payments by the health care system or even pharmaceutical companies. The support for testing from alternative sources, such as the pharmaceutical industry, is no doubt partly compensating for the lack of public health system support, but it is not a viable or long‐term solution. Ideally, a structured access to testing and reimbursement should be the aim in order to provide patients with appropriate therapeutic options. As biomarker enabled therapies deliver a 50% better probability of outcome success, improved and unbiased reimbursement remains a major challenge for the future. AME Publishing Company 2020-06 /pmc/articles/PMC7354119/ /pubmed/32676354 http://dx.doi.org/10.21037/tlcr.2020.04.07 Text en 2020 Translational Lung Cancer Research. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) .
spellingShingle Review Article on Selected Highlights of the 2019 Pulmonary Pathology Society Biennial Meeting
Thunnissen, Erik
Weynand, Birgit
Udovicic-Gagula, Dalma
Brcic, Luka
Szolkowska, Malgorzata
Hofman, Paul
Smojver-Ježek, Silvana
Anttila, Sisko
Calabrese, Fiorella
Kern, Izidor
Skov, Birgit
Perner, Sven
Dale, Vibeke G.
Eri, Zivka
Haragan, Alex
Leonte, Diana
Carvallo, Lina
Prince, Spasenja Savic
Nicholson, Siobhan
Sansano, Irene
Ryska, Ales
Lung cancer biomarker testing: perspective from Europe
title Lung cancer biomarker testing: perspective from Europe
title_full Lung cancer biomarker testing: perspective from Europe
title_fullStr Lung cancer biomarker testing: perspective from Europe
title_full_unstemmed Lung cancer biomarker testing: perspective from Europe
title_short Lung cancer biomarker testing: perspective from Europe
title_sort lung cancer biomarker testing: perspective from europe
topic Review Article on Selected Highlights of the 2019 Pulmonary Pathology Society Biennial Meeting
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7354119/
https://www.ncbi.nlm.nih.gov/pubmed/32676354
http://dx.doi.org/10.21037/tlcr.2020.04.07
work_keys_str_mv AT thunnissenerik lungcancerbiomarkertestingperspectivefromeurope
AT weynandbirgit lungcancerbiomarkertestingperspectivefromeurope
AT udovicicgaguladalma lungcancerbiomarkertestingperspectivefromeurope
AT brcicluka lungcancerbiomarkertestingperspectivefromeurope
AT szolkowskamalgorzata lungcancerbiomarkertestingperspectivefromeurope
AT hofmanpaul lungcancerbiomarkertestingperspectivefromeurope
AT smojverjezeksilvana lungcancerbiomarkertestingperspectivefromeurope
AT anttilasisko lungcancerbiomarkertestingperspectivefromeurope
AT calabresefiorella lungcancerbiomarkertestingperspectivefromeurope
AT kernizidor lungcancerbiomarkertestingperspectivefromeurope
AT skovbirgit lungcancerbiomarkertestingperspectivefromeurope
AT pernersven lungcancerbiomarkertestingperspectivefromeurope
AT dalevibekeg lungcancerbiomarkertestingperspectivefromeurope
AT erizivka lungcancerbiomarkertestingperspectivefromeurope
AT haraganalex lungcancerbiomarkertestingperspectivefromeurope
AT leontediana lungcancerbiomarkertestingperspectivefromeurope
AT carvallolina lungcancerbiomarkertestingperspectivefromeurope
AT princespasenjasavic lungcancerbiomarkertestingperspectivefromeurope
AT nicholsonsiobhan lungcancerbiomarkertestingperspectivefromeurope
AT sansanoirene lungcancerbiomarkertestingperspectivefromeurope
AT ryskaales lungcancerbiomarkertestingperspectivefromeurope